COVID-19 update, 20 Mar

Drug combination works in hospitalized patients!

A small French study shows that an old malaria drug, hydroxychloroquine (HCQ) combined with (AZ) azithromycin.

The graph below shows the percent of patients with a nasal swab that contains the virus.

Black line (control), no change over six days.

Blue line, HCQ alone, nice reduction that is different from control on day 3 but is not cured by day six.

Green line, HCQ plus AZ together, better reduction than HCQ alone and NO VIRUS by day 5!

Caveat: a 20 patient study so results may differ on a big scale but this is a major breakthrough.

Note: my previous analysis of HCQ based on test tube data was that it would fail. I am glad it was tested!

Here is the paper if you want details.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Explore innovative oral drug delivery strategies for breast cancer prevention with Dr. Steven Quay, CEO of Atossa Therapeutics, focusing on reducing breast density and cancer risk.